Novel and Selective Inhibitors of HIV-1 Integrase

In the ongoing battle against the human immunodeficiency virus (HIV), researchers at the University of California, Irvine, have synthesized novel compounds that inhibit the protein HIV Integrase and prevent the virus from replicating, thus providing an alternative to currently available AIDS therapy. Current therapies target the HIV proteins Reverse Transcriptase and Protease, but both these therapies have toxic side effects. Application: These novel, proprietary compounds are potent HIV Integrase inhibitors and show fewer toxic side effects. Furthermore, these compounds block viral replication, target variants of HIV that are resistant to other therapies, and are easily synthesized. In addition to being a potential anti-HIV therapy, these compounds may also act as a research tool to shed light on the molecular mechanisms of HIV and other retroviruses

Type of Offer: Licensing



« More Biotech Patents
« More Pharmaceutical Patents

---